Itovebi (inavolisib)

Itovebi (inavolisib) is an oral, targeted medicine used for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer whose tumours are identified to have a PIK3CA-mutation - one of the most commonly mutated genes in HR-positive disease. Itovebi works by inhibiting the phosphatidylinositol 3-kinase (PI3K) protein, which drives cell growth, proliferation and survival, and plays a pivotal role in disease progression in HR+ breast cancer. Designed with a unique mechanism, Itovebi also works by facilitating the degradation of the mutated PI3K alpha isoform while sparing other isoforms to help minimise the overall burden and toxicity of treatment. 

The Itovebi in combination with palbociclib and fulvestrant is approved in the United States, Switzerland, Canada, Australia, United Arab Emirates and China as a first line treatment for adults with HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer with a PIK3CA-mutation.